Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.66 EUR | +2.10% | +14.05% | +75.83% |
04-17 | Medincell: share price rises following agreement with AbbVie | CF |
04-16 | Medincell, AbbVie to Co-Develop Injectable Therapeutics | DJ |
Sales 2024 * | 13.96M 14.93M 1.2B | Sales 2025 * | 41.88M 44.78M 3.59B | Capitalization | 364M 389M 31.16B |
---|---|---|---|---|---|
Net income 2024 * | -23M -24.59M -1.97B | Net income 2025 * | 2M 2.14M 171M | EV / Sales 2024 * | 29.6 x |
Net Debt 2024 * | 48.73M 52.11M 4.17B | Net Debt 2025 * | 58.83M 62.91M 5.04B | EV / Sales 2025 * | 10.1 x |
P/E ratio 2024 * |
-13.9
x | P/E ratio 2025 * |
-211
x | Employees | 138 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.98% |
Latest transcript on MedinCell S.A.
1 day | +2.10% | ||
1 week | +14.05% | ||
Current month | +32.01% | ||
1 month | +33.12% | ||
3 months | +53.64% | ||
6 months | +120.56% | ||
Current year | +75.83% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 08/01/03 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 31/08/23 |
Chief Tech/Sci/R&D Officer | - | 31/12/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 04/07/17 |
Tone Kvåle
BRD | Director/Board Member | 55 | 12/06/22 |
Virginie Lleu
BRD | Director/Board Member | - | 24/05/16 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 12.66 | +2.10% | 93,879 |
25/04/24 | 12.4 | +2.48% | 121,673 |
24/04/24 | 12.1 | -1.47% | 97,316 |
23/04/24 | 12.28 | +6.23% | 197,954 |
22/04/24 | 11.56 | +4.14% | 138,202 |
Real-time Euronext Paris, April 26, 2024 at 04:37 pm
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+75.83% | 389M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- MEDCL Stock